bioRxivMicrobiology
Pathogenic measles viruses cannot evolve to bypass vaccine-induced neutralizing antibodies
Abstract
After centuries of pestilence and decades of global vaccination, measles serotypes capable of evading vaccine-induced immunity have not emerged. Here, by systematically building mutations into the H-glycoprotein of an attenuated measles strain and assaying for serum neutralization, we show that virus evolution is severely constrained by the existence of numerous codominant H-glycoprotein antigenic sites, some critical for binding to pathogenicity receptors SLAMF1 and Nectin-4. We further demonstrate the existence in serum of protective neutralizing antibodies targeting codominant F-glycoprotein epitopes. Calculations suggest that evolution of pathogenic measles viruses capable of escaping serum neutralization in vaccinated individuals is a near-zero probability scenario.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Uncovering the features of Measles-targeting human antibodies elicited by the MMR vaccine
Marissa Danielle Acciani, Dawid S. Zyla, … Erica Ollmann Saphire·bioRxiv·Sep 9, 2025
- Structural and Mechanistic Basis for Antibody Neutralization of the Measles Fusion Protein
Dawid S. Zyla, Roberta Della Marca, … Matteo Porotto·Nature CommunicationsPeer-reviewed·Apr 6, 2026
- Stabilized Full-Length Measles Fusion Protein Elicits Potent Immunity and Protection In Vivo
Dawid S. Zyla, Gillian Zipursky, … Matteo Porotto·bioRxiv·Oct 7, 2025
- Potent neutralization of Marburg virus by a vaccine-elicited monoclonal antibody
Amin Addetia, Lisa Perruzza, … David Veesler·bioRxiv·May 14, 2025
- A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus
J. A. Jenks, S. Amin, … S. R. Permar·bioRxiv·Jan 19, 2022
- Dual Impacts of a Glycan Shield on the Envelope Glycoprotein B of HSV-1: Evasion from Human Antibodies In Vivo and Neurovirulence
A. Fukui, Y. Maruzuru, … Y. Kawaguchi·bioRxiv·Dec 12, 2022